Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer

Published:2024-02 Issue: Volume:194 Page:104238
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Bao Wanying^ORCID,Li Zhengyu

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference93 articles.

1. Ovarian cancer: epidemiology and risk factors;La Vecchia;Eur. J. Cancer Prev.,2017

2. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer;Winter-Roach;Cochrane Database Syst. Rev.,2012

3. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann. Oncol.,2013

4. Current surgical management of ovarian cancer;Schorge;Hematol. Oncol. Clin. North Am.,2012

5. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N. Engl. J. Med,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune escape between endoplasmic reticulum stress-related cancer cells and exhausted CD8+T cells leads to neoadjuvant chemotherapy resistance in ovarian cancer;Biochemical and Biophysical Research Communications;2024-11

2. The potential of lenvatinib in breast cancer therapy;Medical Oncology;2024-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP